Dr. Avner Ingerman is the Chief Development Officer of Gemini Therapeutics, Inc. Dr. Ingerman brings more than two decades of clinical and development experience to Gemini. Dr. Ingerman started his pharmaceutical industry career at Johnson and Johnson in Israel as R&D and medical affairs director, later assuming international R&D responsibilities in the UK and in the US. He worked as an independent consultant to Ophthalmology development and during his career held various leadership positions, including Head of Ophthalmology at Achillion Pharmaceuticals, Chief Clinical Officer at Ohr Pharmaceuticals, head of Ophthalmology at Regeneron Pharmaceuticals and clinical development leader for Ophthalmology at Johnson and Johnson.
Dr. Ingerman received his B.Sc. in biology, MSc. in Ophthalmology research and M.D. from the Sackler school of medicine, Tel-Aviv University, Israel. He completed his residency in Ophthalmology at the Rabin medical center in Israel.